Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Friday after acquiring Paige, an AI company specializing in digital ...

U.S. equities surged in Friday’s midday trade as investor sentiment buoyed following Federal Reserve Chair Jerome Powell’s ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

In buying Paige, Tempus grows its dataset, expands its tech team and gains a foothold in digital pathology, the company said.

Tempus AI shares were higher after the company said it agreed to buy Paige, an AI company focused on digital pathology, for $81.3 million. The stock was up 8.4% at $83.17 and has more than doubled so ...

Tempus AI shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 88.

Tempus AI (TEM) announced on Friday an acquisition of the AI company specializing in digital pathology, Paige, for $81.25M.

These stocks offer investors exposure to the booming AI market at reasonable valuations. Stock market indices are ...

Tempus is acquiring Paige for $81.25 million, which is being paid predominantly in Tempus common stock, as well as Tempus’ assumption of Paige’s remaining commitment under its existing Microsoft Azure ...

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Cathie Wood’s ARK ETFs have reported their daily trades for Tuesday, August 19th, 2025, with significant activity across a range of stocks. Leading the purchases was Robinhood Markets Inc (NASDAQ: ...